Dendritic cell-based glioma immunotherapy (Review)

  • Authors:
    • Ryuya Yamanaka
    • Naoki Yajima
    • Takashi Abe
    • Naoto Tsuchiya
    • Junpei Homma
    • Miwako Narita
    • Masuhiro Takahashi
    • Ryuichi Tanaka
  • View Affiliations

  • Published online on: July 1, 2003     https://doi.org/10.3892/ijo.23.1.5
  • Pages: 5-15
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Despite advances in radiation and chemotherapy along with surgical resectioning, the prognosis of patients with malignant glioma is poor. Among the new treatments currently being investigated for malignant glioma, immunotherapy is theoretically very attractive, since it offers the potential for high tumor-specific cytotoxicity. There are increasing reports demonstrating that systemic immunotherapy using dendritic cells is capable of inducing an antiglioma response. Therefore, dendritic cell-based immunotherapy could be a new treatment modality for patients with glioma. In this review, we will discuss the implications of these findings for glioma therapy. A literature review of dendritic cell-based glioma immunotherapy was used to overview the dendritic cell in immunobiology, in the central nervous system and in tumor immunology, glioma-associated antigens, dendritic cell therapy in animal glioma model, dendritic cell therapy in clinical trials and future directions in dendritic cell therapy. Dendritic cell-based immunotherapy strategies appear promising as an approach to successfully induce an antitumor immune response and increase survival in patients with glioma. Dendritic cell therapy of glioma seems to be safe and without major side effects. Its efficacy should be further determined in randomized, controlled clinical trials. The development of methods for manipulating dendritic cells for the purpose of vaccination will enhance the clinical usefulness of these cells for biotherapy for malignant glioma.

Related Articles

Journal Cover

July 2003
Volume 23 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yamanaka, R., Yajima, N., Abe, T., Tsuchiya, N., Homma, J., Narita, M. ... Tanaka, R. (2003). Dendritic cell-based glioma immunotherapy (Review). International Journal of Oncology, 23, 5-15. https://doi.org/10.3892/ijo.23.1.5
MLA
Yamanaka, R., Yajima, N., Abe, T., Tsuchiya, N., Homma, J., Narita, M., Takahashi, M., Tanaka, R."Dendritic cell-based glioma immunotherapy (Review)". International Journal of Oncology 23.1 (2003): 5-15.
Chicago
Yamanaka, R., Yajima, N., Abe, T., Tsuchiya, N., Homma, J., Narita, M., Takahashi, M., Tanaka, R."Dendritic cell-based glioma immunotherapy (Review)". International Journal of Oncology 23, no. 1 (2003): 5-15. https://doi.org/10.3892/ijo.23.1.5